Live Breaking News & Updates on Manifest 2

Stay updated with breaking news from Manifest 2. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Raajit K. Rampal, MD, PhD, presents data from the MANIFEST-2 study investigating pelabresib in combination with ruxolitinib in Janus kinase inhibitor treatment–naïve patients with myelofibrosis. ....

United States , San Diego , Raajitk Rampal , Janus Kinase Inhibitor Treatment Na , Partnership With , Total Symptom Score , North America , Manifest 2 , Manifest 2 Study , Manifest 2 Trial , Jak Inhibitor , Mash 2023 , Manifest 2 Data , Manifest 2 Results ,

Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm

Prithviraj Bose, MD, discusses the development of non-myelosuppressive JAK inhibitors for patients with myelofibrosis, where the future of combination therapy is headed in this population, and the importance of enrolling patients in clinical trials that are tailored to their disease subset and treatment needs. ....

United States , Prithviraj Bose , Division Of Cancer Medicine , University Of Texas Md Anderson Cancer Center , Department Of Leukemia , Cancer Medicine , Cancer Center , Bet Inhibitor Pelabresib , Jak Inhibitor Combination , Manifest 2 ,